- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02181504
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
March 14, 2017 updated by: Allergan
This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chiyoda-ku,Tokyo, Japan, 101-8309
- Nihon University Hospital
-
Fukushima-shi, Japan, 960-1295
- 1 Fukushima Medical University
-
Kita-ku, Fukuoka-shi Fukuoka, Japan, 812-8582
- Kyushu University Hospital
-
Kita-ku, Okayama-shi Okayama, Japan, 700-8558
- Okayama University Hospital
-
Otsu-shi, Japan, 520-2192
- Shiga University
-
Shinjuku-ku, Japan, 162-8666
- Tokyo Women's Medical University
-
Showa-ku, Nagoya-shi Aichi, Japan, 466-8560
- Nagoya University Hospital
-
Taito Ku Tokyo, Japan, 111-0051
- Takeuchi eye clinic
-
Tennoji-ku Osaka, Japan, 543-0027
- Musashi Dream Clinic
-
Urayasu-shi, Japan, 279-0021
- Juntendo University Urayas
-
Yamato Kanagawa, Japan, 242-0001
- Otakeganka Tsukimino Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ethnically Japanese
- Diagnosis of wet age-related macular degeneration in at least 1 eye
- Best corrected visual acuity of 20/32 to 20/320 in the study eye and 20/200 or better in the fellow eye
Exclusion Criteria:
- Hypersensitivity, allergy, or anaphylactic reaction to iodine or shellfish
- Cataract or refractive surgery within the last 3 months
- History of vitrectomy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: abicipar pegol 2 mg
Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
|
Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
Sham procedure to the study eye at weeks 12 and 16.
|
Experimental: abicipar pegol 1 mg
Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
|
Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
Sham procedure to the study eye at weeks 12 and 16.
|
Active Comparator: ranibizumab 0.5 mg
Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
|
Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
Time Frame: Baseline, Week 16
|
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye.
The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity).
An increase (positive number change from baseline) in the number of letters read correctly means that vision has improved and a decrease (negative number change from baseline) in the number of letters read correctly means that vision has worsened.
|
Baseline, Week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in BCVA in the Study Eye
Time Frame: Baseline, Week 20
|
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye.
The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity).
An increase (positive number change from baseline) in the number of letters read correctly means that vision has improved and a decrease (negative number change from baseline) in the number of letters read correctly means that vision has worsened.
|
Baseline, Week 20
|
Percentage of Patients With a BCVA Gain of ≥15 Letters in the Study Eye on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale
Time Frame: Baseline, 20 Weeks
|
BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye.
The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity).
An increase in the number of letters read correctly means that vision has improved.
The percentage of patients with a BCVA gain of ≥15 letters are noted.
|
Baseline, 20 Weeks
|
Percentage of Patients With a BCVA Gain of ≥10 Letters in the Study Eye on the ETDRS Scale
Time Frame: Baseline, 20 Weeks
|
BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye.
The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity).
An increase in the number of letters read correctly means that vision has improved.
The percentage of patients with a BCVA gain of ≥10 letters are noted.
|
Baseline, 20 Weeks
|
Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye
Time Frame: Baseline, Week 16, Week 20
|
CRT is assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system that provides high-resolution imaging sections of the retina.
SD-OCT is performed in the study eye after pupil dilation.
A negative change from Baseline indicates improvement and a positive change from baseline indicates worsening.
|
Baseline, Week 16, Week 20
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2014
Primary Completion (Actual)
December 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
July 2, 2014
First Submitted That Met QC Criteria
July 2, 2014
First Posted (Estimate)
July 4, 2014
Study Record Updates
Last Update Posted (Actual)
April 25, 2017
Last Update Submitted That Met QC Criteria
March 14, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 150998-002
- BAMBOO (Allergan)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Centre Hospitalier Intercommunal CreteilCompletedMacular Degeneration Exudative Eye Left | Macular Degeneration Exudative Eye RightFrance
-
University of Modena and Reggio EmiliaCompletedMacular Degeneration Advanced | Macular Degeneration, Dry | Macular Degeneration, Senile | Macular Scar | Macular Degeneration NonexudativeItaly
-
Shanghai Refreshgene Technology Co., Ltd.RecruitingNeovascular Age-related Macular DegenerationChina
-
PharmAbcineC&R Research, Inc.RecruitingNeovascular Age-related Macular DegenerationKorea, Republic of
Clinical Trials on abicipar pegol
-
AllerganCompletedMacular DegenerationUnited States
-
AllerganCompletedMacular DegenerationUnited States
-
AllerganCompleted
-
AllerganCompleted
-
AllerganCompletedMacular DegenerationUnited States
-
AllerganCompletedMacular DegenerationUnited States, Japan, United Kingdom, Italy, Taiwan, Australia, Canada, Hungary, Poland, Russian Federation, Netherlands, Brazil, Denmark, Peru, South Africa, Turkey
-
AllerganCompletedMacular DegenerationSpain, United States, Korea, Republic of, Israel, Singapore, Argentina, Germany, France, Czechia, Austria, Philippines, Switzerland, Chile, Colombia, Hong Kong, Latvia, New Zealand
-
Novo Nordisk A/SActive, not recruiting
-
Novo Nordisk A/SEnrolling by invitationHaemophilia BNetherlands, United Kingdom
-
Novo Nordisk A/SEnrolling by invitationHaemophilia BCanada, United Kingdom, Czechia, Germany, Greece, Austria, Belgium, Croatia, Denmark, Finland, Norway, Portugal